Brief: Landos Biopharma Inc - First Patient Dosed In A Phase 2 Study Of Omilancor For Moderate-To-Severe Crohn's Disease
06/05/2021 21:10
May 6 (Reuters) - Landos Biopharma Inc LABP.O :
* LANDOS BIOPHARMA INC - FIRST PATIENT DOSED IN A PHASE 2
STUDY OF
OMILANCOR FOR MODERATE-TO-SEVERE CROHN'S DISEASE
* LANDOS BIOPHARMA INC - SECOND OMILANCOR PROGRAM ENTERING A
PHASE
2 STUDY WITH PLANS TO PURSUE AT LEAST FIVE AUTOIMMUNE
INDICATIONS
Source text for Eikon: ID:nGNX468Pht
Further company coverage: LABP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Landos Biopharma
See all newsLandos Biopharma Inc expected to post a loss of 100 cents a share - Earnings Preview
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Super Micro, Micron Technology, Navios Maritime
U.S. STOCKS ON THE MOVE-Landos Biopharma, Foot Locker, US energy sector
Brief: AbbVie To Acquire Landos Biopharma